| Name | Betahistine dihydrochloride |
| Description | Betahistine dihydrochloride (Betahistine 2HCl) is a histamine analog and H1 receptor agonist that serves as a vasodilator. |
| In vitro | In mice, Betahistine (ED50=2 mg/kg) elevates t-MeHA levels in a dose-dependent manner. In patients with Ménière's disease, Betahistine (16 mg, twice daily for 3 months) significantly alleviates vertigo. Additionally, Betahistine (50 mg/kg) induces an upregulation of histidine decarboxylase mRNA in the nodose ganglion of the cat brain. |
| In vivo | In CHO(H3R) cells treated with 3 μM of, Betahistine progressively increased cAMP formation, peaking at 10 nM. Furthermore, in CHO(H3R) cells, Betahistine progressively reduced A23187-induced [3H]arachidonic acid release (EC50=0.1 nM), with the greatest effect observed at 30 nM. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (239.1 mM), Sonication is recommended. H2O : 35 mg/mL (167.37 mM), Sonication is recommended. Ethanol : 1 mg/mL (4.78 mM), Sonication is recommended.
|
| Keywords | schizophrenia | Rheumatoid | PT9 | PT 9 | Ménière | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H3 receptor | episode | disease | CIA | Betahistine Dihydrochloride | Betahistine | arthritis | antipsychotic |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |